Added to YB: 2024-08-02
Pitch date: 2024-06-30
BPMC [bullish]
Blueprint Medicines Corporation
+20.23%
current return
Author Info
No bio for this author
Company Info
Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally.
Market Cap
$8.4B
Pitch Price
$107.68
Price Target
N/A
Dividend
N/A
EV/EBITDA
-60.94
P/E
-52.77
EV/Sales
14.58
Sector
Biotechnology
Category
growth
ClearBridge Small Cap Growth Strategy New Position: Blueprint Medicines Corporation
BPMC: Biopharma w/ approved rare disease drug, blockbuster potential. Early launch, path to profitability as product ramps. Expertise in allergy/immunology & oncology/hematology. Pipeline optionality in allergies/respiratory/immunology. Health care sector focus, near-term profit inflection expected.
Read full article (1 min)